Bio-link Australia Pty. Ltd.

7th November 2013 – Deal between Centenary Institute and Mirrx Therapeutics

Bio-Link has facilitated execution of a strategic Collaboration and Commercialisation Agreement between Centenary Institute of Cancer Medicine and Cell Biology (Sydney, Australia) and Mirrx Therapeutics A/S (Vejle, Denmark) to discover and develop therapeutic “Blockmir” oligonucleotide drug candidates targeting vascular endothelial cadherin (VE-cadherin) to treat pathological conditions including ischemia, inflammation, oedema and solid tumours. Lead drug candidate, CD5-2, a novel, potent 15-mer oligonucleotide drug potently inhibits vascular permeability and promotes angiogenesis in vivo,  leading to increased blood flow, decreased oedema and faster recovery, for example, in the industry standard hind limb ischemia mouse model.

Click here for the full press release

combined logos